


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of all claims in the application.


Listing of Claims

1. **(Currently amended)** A method of inhibiting angiogenesis in a host with an angiogenic disease, ~~consisting essentially of~~ comprising contacting said host with a cephalotaxine in an amount sufficient to inhibit angiogenesis, wherein said angiogenic disease is not a solid tumor and wherein angiogenesis is inhibited in said host.
2. **(Original)** The method of claim 1 wherein the angiogenic disease is selected from the group consisting of an inflammatory disease, diabetic retinopathy, or macular degeneration.
3. **(Original)** The method of claim 2 wherein the inflammatory disease is selected from the group consisting of rheumatoid arthritis, osteoarthritis, asthma, and pulmonary fibrosis.
4. **(Original)** The method of claim 1 wherein the cephalotaxine comprises homoharringtonine (cephalotaxine, 4-methyl-2-hydroxy-2-(4-hydroxy-4-methyl pentyl) butanedioate ester).
5. **(Previously presented)** The method of claim 1 wherein the cephalotaxine comprises a compound of the formula



wherein R₁ is an ester or a substituted alkyl and wherein R₂ is an ester or a substituted alkyl.

6. **(Previously Presented)** The method of claim 1, wherein said contacting comprises the administration of said cephalotaxine by a route selected from the group consisting of oral, intravenous, topical, intravascular, intraperitoneal, intramuscular, intradermal, subcutaneous and intraarterial.
7. **(Previously Presented)** A method of inhibiting the onset or progression of an angiogenic disease in a host, comprising contacting said host with a cephalotaxine in amount sufficient to inhibit the onset or progression of an angiogenic disease, wherein angiogenesis is inhibited in said host.
8. **(Original)** The method of claim 7, wherein the angiogenic disease is cancer.
9. **(Previously presented)** The method of claim 8, wherein the cancer is characterized by cancer cells that have not yet been vascularized to form a solid tumor.
10. **(Original)** The method of claim 7, wherein the angiogenic disease is an angiogenic disease other than cancer.
11. **(Original)** The method of claim 7, wherein the angiogenic disease is selected from the group consisting of an inflammatory disease, diabetic retinopathy, or macular degeneration.
12. **(Original)** The method of claim 11, wherein the inflammatory disease is selected from the group consisting of rheumatoid arthritis, osteoarthritis, asthma, and pulmonary fibrosis.
13. **(Original)** The method of claim 7, wherein the cephalotaxine comprises homoharringtonine (cephalotaxine, 4-methyl-2-hydroxy-2-(4-hydroxy-4-methyl pentyl) butanediocate ester).
14. **(Previously presented)** The method of claim 7, wherein the cephalotaxine comprises a compound of the formula



wherein R_1 is an ester or a substituted alkyl and wherein R_2 is an ester or a substituted alkyl.

15. **(Previously presented)** The method of claim 5 or 14, wherein said cephalotaxine is selected from the group consisting of harringtonine, isoharrintonine, homoharringtonine, deoxyharringtonine, and acetylcephalotaxine.